To examine whether BRG1 might be regulated by NPM-ALK tyrosine kinase activity in ALK+ ALCL cell lines, SU-DHL-1 cells were treated with the ALK inhibitor Crizotinib for 6 h (Figure 2a). The gene discussed is SMARCA4; the disease is anaplastic large cell lymphoma.